Polyclonal Antibody to Mitogen Activated Protein Kinase 8 (MAPK8)
| Code | Size | Price |
|---|
| PAB156Hu01-20ul | 20ul | £84.00 |
Quantity:
| PAB156Hu01-100ul | 100ul | £155.00 |
Quantity:
| PAB156Hu01-200ul | 200ul | £208.00 |
Quantity:
| PAB156Hu01-1ml | 1ml | £475.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
MAPK8; JNK1A2; JNK21B1/2; PRKM8; SAPK1; JUN N-Terminal Kinase; Stress-activated protein kinase 1c; Mitogen Activated Protein Kinase 8
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
c-Jun N-terminal Kinase 1
Reactivity:
Mu;Ra;Gu;Ca;Po;Bo;Cp;Ov;Eq;Ga;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.01-2ug/mL;<br/>Immunohistochemistry: 5-20ug/mL;<br/>Immunofluorescence: 5-20ug/mL<br/>Optimal working dilutions must be determined by end user.
References
https://pubmed.ncbi.nlm.nih.gov/32703964/; https://cmbl.biomedcentral.com/articles/10.1186/s11658-023-00430-3;
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Mitogen Activated Protein Kinase 8 (MAPK8) | RPB156Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||